GLP-1 Receptor Agonist Medicines: What Is Approved Now

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub, where we connect GLP-1 science, weight-management protocols, and the genetics beneath every metabolic choice. Browse all Peptides & GLP-1 education.

"GLP-1 receptor agonist medicines" is a question about what is actually on the shelf: which products have FDA approval, which are still in trials, and what separates them. This guide leads with the approved medicines and their approval timeline, then explains how they work and where genetics fit.

The approved medicines and when they arrived

The FDA-approved GLP-1 receptor agonist class includes exenatide (Byetta, 2005; Bydureon), liraglutide (Victoza, 2010; Saxenda, 2014), dulaglutide (Trulicity, 2014), semaglutide (Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021), and tirzepatide (Mounjaro, 2022; Zepbound, 2023, expanded to obstructive sleep apnea in 2024). The timeline shows how quickly the class has broadened from a single diabetes drug into multiple indications.

What is still investigational

Not every "GLP-1 medicine" you read about is available. Investigational compounds in late-stage development include retatrutide, a GIP/GLP-1/glucagon triple agonist, and orforglipron, an oral non-peptide small-molecule GLP-1 receptor agonist. Both have generated data but are not FDA-approved, meaning they cannot be prescribed as approved medicines yet.

What GLP-1 actually is

GLP-1, glucagon-like peptide-1, is an incretin hormone secreted by intestinal L-cells in response to food. Native GLP-1 is a 30- to 31-amino-acid peptide with a half-life of about two minutes, because the enzyme DPP-4 degrades it rapidly. It governs post-meal insulin release, gastric emptying, and satiety signaling.

How these medicines work

GLP-1 receptor agonist medicines are engineered to resist DPP-4 degradation, extending half-life from minutes to days or weeks. They bind the same receptor as the native hormone, driving insulin secretion, glucagon suppression, delayed gastric emptying, and satiety. Tirzepatide-based medicines add agonism at the GIP receptor, a related incretin receptor and one of the key molecular distinctions in the class as of April 2026.

Why genetic context matters

These medicines engage a receptor pathway with natural genetic variation, so results are not uniform. GLP1R, the receptor gene, influences receptor density and signaling efficiency; FTO shapes appetite and adiposity set-point; MC4R affects hypothalamic satiety and energy intake; and TCF7L2 influences insulin secretion and incretin response. These pathway-level variants do not predict response to any one medicine.

Where PlexusDx fits

The PlexusDx Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights across those variants, describing the terrain before any protocol. PlexusDx offers GLP-1 receptor agonists through its Weight Management Protocols. For deeper reading, see What Is GLP-1? and GLP-1 Drugs.

Approved versus available versus investigational

Three words that sound similar cause most of the confusion here. Approved means the FDA has cleared a medicine for specific indications. Investigational means a compound is still being studied and cannot be prescribed as an approved product, no matter how much coverage it receives. Reading about a promising triple agonist is not the same as being able to fill it at a pharmacy.

Keeping those categories straight protects you from two common mistakes: assuming everything discussed in the news is purchasable, and assuming an approved medicine is automatically the right one for your indication. Approval status and personal suitability are different questions, and only a prescriber can answer the second after evaluating your situation.

It also helps to separate the medicine from the mechanism when you read coverage. Much of what is written about GLP-1 medicines describes the class effect, the shared appetite and glucose biology, rather than anything unique to a single product. Understanding that shared foundation makes the news easier to interpret: when a new agent is described as working through the GLP-1 pathway, you already know the general shape of what it does, even if its receptor targets or dosing interval differ.

Finally, the pace of change here is a reason to check dates. A compound that is investigational in one year may be approved in another, and an article written earlier can describe a landscape that has since shifted. Anchoring your understanding to the mechanism, then verifying current approval status, keeps you from mistaking an older snapshot for the current set of options.

Frequently Asked Questions

Which GLP-1 receptor agonist medicines are FDA-approved?

As of April 2026, approved medicines include exenatide, liraglutide, dulaglutide, and semaglutide, plus the GIP/GLP-1 dual agonist tirzepatide. Each brand carries its own indications. Retatrutide and orforglipron remain investigational and are not approved medicines that a provider can prescribe today.

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1, an incretin hormone released by intestinal L-cells after meals. It supports insulin secretion, slows gastric emptying, and signals fullness. GLP-1 receptor agonist medicines reproduce these effects by activating the same receptor over a much longer window than the natural hormone.

Are these medicines the same as GLP-1 inhibitors?

No. These medicines are agonists that activate the GLP-1 receptor, not inhibitors that block it. The term "inhibitor" does not describe this class. The therapeutic goal is sustained receptor activation to reproduce the hormone's metabolic effects on glucose and appetite.

Does genetic testing tell me which medicine to take?

No. The Precision Peptide Genetic Test does not predict response to any medicine or select one for you. It analyzes pathway-level variants in GLP1R, FTO, MC4R, and TCF7L2 that shape baseline biology, offering context you and your provider can use alongside a clinical evaluation.

This guide lives in the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.